{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:40:50Z","timestamp":1790620850069,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Type 1 diabetes (T1D) and hidradenitis suppurativa (HS) share several metabolic and inflammatory dysfunctions. Prior studies of the potential link between the diseases either lacked validated T1D diagnoses or established only an indirect association. This study sought to determine the odds of HS developing in patients with a validated diagnosis of T1D and to characterize the clinical features of HS\/T1D comorbidity. Methods: A population-based nested case-control study was conducted including patients with HS and controls matched 5:1 for age, sex, and primary care clinic. T1D was diagnosed using a specialized algorithm, achieving 90% accuracy. Diagnostic validity was confirmed by diabetes specialists who manually reviewed a random subset of the files. Unadjusted and adjusted odds ratios (OR\/aOR) were calculated to determine the odds of incident HS in patients with T1D. Results: The study included 10,919 patients with HS and 53,314 controls. A history of T1D was associated with an elevated odds of new-onset HS (OR 1.80 95% CI (1.30\u20132.40), p &lt; 0.001), even after adjusting for demographics and metabolic and autoimmune comorbidities (aORs &gt; 1.7, p &lt; 0.001). Patients with HS\/T1D comorbidity had higher proportions of autoimmune conditions than patients with HS alone (p &lt; 0.001) and a higher mean Charlson Comorbidity Index score than both patients with HS alone (3.5 vs. 0.9, p &lt; 0.001) and T1D alone (3.5 vs. 2.2, p = 0.004). Conclusions: T1D is associated with higher odds of the subsequent development of HS. Awareness of HS\/T1D comorbidity is recommended owing to the elevated burden of metabolic and autoimmune conditions.<\/jats:p>","DOI":"10.3390\/jcm14082625","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:45:31Z","timestamp":1744353931000},"page":"2625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Type 1 Diabetes\/Hidradenitis Suppurativa Comorbidity\u2014A Population-Based Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2323-3512","authenticated-orcid":false,"given":"Shany","family":"Sherman","sequence":"first","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Slama","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yochai","family":"Schonmann","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Medicine & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv 6209804, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv 6209804, Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossef H.","family":"Taieb","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mimouni","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Peretz","sequence":"additional","affiliation":[{"name":"Division of Community Medical Services, Clalit Health Services, Tel Aviv 6209804, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Duskin-Bitan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Institute of Endocrinology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: A systematic review and meta-regression analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjd.18135","article-title":"A qualitative analysis of psychological distress in hidradenitis suppurativa","volume":"182","author":"Keary","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdin.2020.05.005","article-title":"Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: An update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/ijd.15319","article-title":"Hidradenitis suppurativa is associated with hypothyroidism and hyperthyroidism: A large-scale population-based study","volume":"60","author":"Sherman","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.34172\/hpp.2020.18","article-title":"Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis","volume":"10","author":"Mobasseri","year":"2020","journal-title":"Health Promot. Perspect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00125-024-06086-8","article-title":"Autoimmune comorbidity in type 1 diabetes and its association with metabolic control and mortality risk in young people: A population-based study","volume":"67","author":"Samuelsson","year":"2024","journal-title":"Diabetologia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e009952","DOI":"10.1136\/bmjopen-2015-009952","article-title":"Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations","volume":"6","author":"Khokhar","year":"2016","journal-title":"BMJ Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2337\/dc12-0964","article-title":"Automated detection and classification of type 1 versus type 2 diabetes using electronic health record data","volume":"36","author":"Klompas","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1458-P","DOI":"10.2337\/db23-1458-P","article-title":"Challenges for the diagnostic classification of type 1 diabetes (T1D) among older adults in electronic health record (EHR) data","volume":"72","author":"Weinstein","year":"2023","journal-title":"Diabetes"},{"key":"ref_15","first-page":"e009088","article-title":"Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature","volume":"5","author":"Shields","year":"2015","journal-title":"MJ Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.amepre.2016.07.030","article-title":"A most odd ratio: Interpreting and describing odds ratios","volume":"52","author":"Persoskie","year":"2017","journal-title":"Am. J. Prev. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000468148","article-title":"Validation of a case-finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database","volume":"233","author":"Strunk","year":"2017","journal-title":"Dermatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.13041","article-title":"The validity of the diagnostic code for hidradenitis suppurativa in an electronic database","volume":"171","author":"Kim","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.15071","article-title":"Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: A nationwide population-based study","volume":"32","author":"Lee","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamadermatol.2020.1281","article-title":"Disease trajectories for hidradenitis suppurativa in the Danish population","volume":"156","author":"Reguant","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1111\/add.15963","article-title":"Association of opioid use disorder with healthcare utilization and cost in a public health system","volume":"117","author":"Miron","year":"2022","journal-title":"Addiction"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pcd.2019.09.009","article-title":"Characteristics of newly diagnosed adults with type 1 diabetes in the UK and evolution of glycaemic control, body mass index and Charlson comorbidity index over the first 5 years after diagnosis","volume":"14","author":"Ramtoola","year":"2020","journal-title":"Prim. Care Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2018). 3. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes-2018. Diabetes Care, 41, S28\u2013S37.","DOI":"10.2337\/dc18-S003"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2019.06.016","article-title":"All-cause mortality among patients with hidradenitis suppurativa: A population-based cohort study in the United States","volume":"81","author":"Reddy","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2018.01.014","article-title":"Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States","volume":"79","author":"Garg","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.2000.00705.x","article-title":"Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors","volume":"248","author":"Lechleitner","year":"2000","journal-title":"J. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.2337\/db10-1643","article-title":"Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated \u03b2-cell death","volume":"60","author":"Arif","year":"2011","journal-title":"Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Starosz, A., Jamio\u0142kowska-Sztabkowska, M., G\u0142owi\u0144ska-Olszewska, B., Moniuszko, M., Bossowski, A., and Grubczak, K. (2022). Immunological balance between Treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.958430"},{"key":"ref_29","first-page":"260","article-title":"T helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: The link to hair follicle dissection, obesity, smoking and autoimmune comorbidities","volume":"179","author":"Melnik","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1122","DOI":"10.1002\/cti2.1122","article-title":"Cytokines in type 1 diabetes: Mechanisms of action and immunotherapeutic targets","volume":"9","author":"Lu","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Irvin, A.E., Jhala, G., Zhao, Y., Blackwell, T.S., Krishnamurthy, B., Thomas, H.E., and Kay, T.W.H. (2018). NF-\u03baB is weakly activated in the NOD mouse model of type 1 diabetes. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-22738-3"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Krajewski, P.K., Z\u0142otowska, A., and Szepietowski, J.C. (2024). The Therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: A systematic review of anti-inflammatory and metabolic effects. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216292"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): A new weight loss drug for chronic weight management","volume":"70","author":"Singh","year":"2022","journal-title":"J. Investig. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMc2302677","article-title":"Semaglutide in early type 1 diabetes","volume":"389","author":"Dandona","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljae216","article-title":"Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: Its impact on disease control and quality of life","volume":"191","author":"Lyons","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: Glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bazile, C., Abdel Malik, M.M., Ackeifi, C., Anderson, R.L., Beck, R.W., Donath, M.Y., Dutta, S., Hedrick, J.A., Karpen, S.R., and Kay, T.W.H. (2024). TNF-\u03b1 inhibitors for type 1 diabetes: Exploring the path to a pivotal clinical trial. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1470677"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:46Z","timestamp":1760029966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082625"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082625","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}